Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.53 |
| ▸ | CNR2 | P34972 | 14/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092456 | 0.99 | CNR1 (0.54) | CNR1CNR2FAAH | |
| SCHEMBL3100230 | 0.85 | CNR1 (0.51) | CNR1CNR2FAAHNPC1RAB9A | |
| SCHEMBL3087783 | 0.82 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL3097503 | 0.81 | RPA1 (0.67) | — | |
| SCHEMBL3100250 | 0.81 | RPA1 (0.54) | CNR1 | |
| SCHEMBL17203783 | 0.80 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL3096616 | 0.80 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL3092191 | 0.79 | CNR2 (0.75) | CNR1CNR2 | |
| SCHEMBL3099106 | 0.79 | CNR2 (0.75) | CNR1CNR2 | |
| SCHEMBL3100236 | 0.79 | CNR1 (0.50) | CNR1CNR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803799-B2 | such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-09-28 | — | — | US | disclosed |
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021031-A1 | SELENOPHENE COMPOUNDS | CNR2, CNR1, SELENOI | CNR1 2/4885CNR2 1/4885FAAH 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.